UVA Health Researchers Identify How Alzheimer’s Risk Gene CASS4 Regulates Brain’s Immune Cells, Offering New Therapeutic Target

UVA Health researchers have identified how the Alzheimer’s risk gene CASS4 regulates the brain’s immune cells, finding that its disruption accelerates toxic plaque buildup and cognitive decline in mice.

The study, published this week in the Journal of Experimental Medicine, shifts the scientific paradigm by proving CASS4 acts primarily through microglia — the brain’s resident immune cells — rather than neurons, ScienceDaily reported. This mechanism positions the brain’s cleanup system as a potential therapeutic target for a disease affecting more than 6 million Americans.

“These findings break new ground in our understanding of how this genetic risk factor contributes to Alzheimer’s disease,” said John Lukens, PhD, director of UVA’s Harrison Family Translational Research Center in Alzheimer’s and Neurodegenerative Diseases.

“Our work further suggests that defective CASS4 activity may serve as an early-onset biomarker to detect Alzheimer’s and that therapeutic strategies which boost its function may offer a much-needed approach to treat this devastating brain disease.”

Addie Walsh, a UVA physiology graduate student and the study’s first author, emphasized the knowledge gap the work addresses. “Despite CASS4 being an Alzheimer’s risk gene, really nothing is known about what this gene does or how it affects the brain during disease,” Walsh said.

“These are important findings because they give us new insight into how this understudied AD risk gene functions in the brain and suggest that CASS4 may normally help microglia respond to amyloid pathology.”

Microglia lose containment ability without functional CASS4

Microglia normally surround amyloid-beta plaques, forming protective barriers and compressing the deposits into dense, less harmful structures. The UVA team discovered that CASS4 is essential for this containment process. In laboratory mice where the gene was disrupted, microglia failed to adequately surround and compact plaques.

The result was a cascade of pathology: amyloid deposits accumulated more aggressively, nearby neurons suffered damage, and the animals exhibited measurable cognitive decline. The research also revealed that losing CASS4 triggered widespread changes in the activity of other genes, a finding the investigators suspect may extend to other neurodegenerative disorders, though that involvement remains under investigation.

Paradigm shift from neurons to neuroimmunology

For years, the prevailing hypothesis placed CASS4‘s function within neurons, the cells responsible for transmitting brain signals. The new data definitively redirects that focus toward the innate immune system.

“Many in the field initially presumed that CASS4 was likely functioning in neurons to influence Alzheimer’s,” Lukens said. “Our findings shift this paradigm by proving that CASS4 predominantly acts through the immune system. This is particularly exciting, as it has only been in recent years that immune-targeting strategies have been considered for the treatment of neurodegenerative diseases, and this remains an untapped therapeutic avenue with tremendous potential.”

This alignment with neuroimmunology mirrors the mechanism of recently approved anti-amyloid monoclonal antibodies — such as lecanemab and donanemab — which rely on microglial activation to clear plaques. However, those therapies carry risks of amyloid-related imaging abnormalities (ARIA), including brain swelling and microhemorrhages. A strategy enhancing endogenous CASS4 function theoretically offers a more physiological modulation of microglial activity, though this remains hypothetical.

In Plain English: The Clinical Takeaway

  • A known risk gene has a known job: CASS4 isn’t just a statistical marker; it directs the brain’s “janitor cells” (microglia) to wall off toxic amyloid plaques.
  • Broken gene, faster disease: When CASS4 fails, plaques spread faster, neurons die sooner, and memory worsens — at least in mouse models.
  • Drugs boosting CASS4 or microglial fitness could theoretically slow disease earlier than current antibody infusions, but human trials are years away.

From mouse models to human medicine: the translational gap

The experiments were conducted in murine models, a critical limitation acknowledged by the authors. While mouse microglia share core functions with human cells, important differences in gene expression, immune response, and amyloid pathology progression exist. The National Institute on Aging (NIA) has increasingly stressed the need for humanized models and induced pluripotent stem cell (iPSC)-derived microglia to close this gap before clinical translation.

Funding for the work came from the NIA via grants R01AG071996, R01AG087406, RF1AG078684, and R01AG086344, alongside philanthropic support from the Cure Alzheimer’s Fund, the Owens Family Foundation, the Harrison Family Foundation, the Rick Sharp Foundation, and the Steven A. Newman AD Award. The researchers reported no financial conflicts of interest.

Geographically, the research sits within UVA’s Paul and Diane Manning Institute of Biotechnology, an entity designed to accelerate the “bench-to-bedside” pipeline. Lukens is the director of the Harrison Family Translational Research Center in Alzheimer’s and Neurodegenerative Diseases. Walsh, the first author, is a UVA physiology graduate student.

Parameter Current Anti-Amyloid mAbs (Lecanemab/Donanemab) Hypothetical CASS4-Targeted Therapy
Primary Mechanism Exogenous antibody binds amyloid; recruits microglia via Fc receptors Endogenous enhancement of microglial containment/compaction
Regulatory Status FDA Approved (Traditional/Accelerated) Preclinical (Mouse models only)

Contraindications & When to Consult a Doctor

No clinical test for CASS4 function exists, and no therapy targeting this pathway is available for human use. Patients and families should not seek genetic testing for CASS4 variants outside of a research protocol; the variants identified in genome-wide association studies (GWAS) confer modest risk increases, not deterministic outcomes.

Individuals experiencing progressive memory loss, difficulty with familiar tasks, or changes in judgment should consult a neurologist or geriatrician for a standard diagnostic workup — including cognitive screening, blood biomarkers (where available), and structural imaging.

Next steps: Biomarker validation and target druggability

The UVA team is actively exploring CASS4‘s role in other neurodegenerative disorders and developing strategies to therapeutically target the pathway. Key hurdles remain: determining if CASS4 expression levels in blood or cerebrospinal fluid correlate with disease stage in humans, assessing the “druggability” of the protein’s structure, and evaluating whether boosting microglial compaction function in aged human brains — where microglial senescence is prevalent — is beneficial or detrimental.

“We are now actively exploring potential roles for CASS4 in multiple other neurodegenerative disorders and developing novel strategies to therapeutically target it,” Lukens said.

UVA Health traces its origins to the University of Virginia’s founding in 1819, when a School of Medicine was authorized at the first Board of Visitors meeting. The nation’s 10th medical school opened in March 1825 under a single professor, Dr. Robley Dunglison, recruited by Thomas Jefferson from London.

The University of Virginia Hospital opened in March 1901 with 25 beds and three operating rooms, later adding a nursing training program that became the formal School of Nursing in 1956. Today the academic health system includes a 701-bed medical center, a Level I trauma center, and schools of medicine and nursing whose leading research areas include neurodegenerative diseases and vaccine development.

References

  • Walsh AE, Davis BA, Samuels JD, et al…
  • National Institute on Aging. Updated 2024.
  • van Dyck CH, et al.
  • Sims JR, et al.
  • Keren-Shaul H, et al.

Disclaimer: This article reports on preclinical research findings and does not constitute medical advice. Consult a qualified healthcare provider for diagnosis and treatment decisions.

Photo of author

Health Desk

Health Desk at Archyde.

LeBron James Organizes Private ‘I Play Rocky’ Screening for 76ers Teammates, Staff

Mountain-Sized Asteroid 1999 AN10 to Pass Near Earth in August 2027